$ about // editorial
About Sermorelin Order
An independent editorial project that reads the published sermorelin literature and sets the compound beside the secretagogues it is compared with.
What this site is
Sermorelin Order is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin — the GHRH(1-29) peptide and pituitary GH secretagogue. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The name reflects the way this site is built, not a service it offers. "Order" here is the terminal sense of the word — a command issued at a prompt, a query placed against the literature, the deterministic order of operations in the GH/IGF-1 cascade. It is not a checkout, a cart, or a storefront. Nothing on this site is for sale, and no part of it dispenses, prescribes, or sources sermorelin.
How we read the literature
The editorial method is plain: lead with what a study measured, attribute it to the source, and keep the gaps visible. Where the evidence is strong — the pediatric height-velocity result [1], the reversal of age-related GH/IGF-1 decline in older men [2] — we say so. Where it is weak or borrowed from a related analogue — the body-composition and cognition data that come from tesamorelin rather than sermorelin [6] — we mark that distinction rather than blur it.
We are also careful with the regulatory record, because it is frequently misstated. Sermorelin was an FDA-approved drug for pediatric GH deficiency and was withdrawn from the US market in 2008 for commercial reasons, not for safety or efficacy. It is now prepared by compounding pharmacies and treated as a Category 1 bulk drug substance under the FDA's Section 503A framework. We state that history as filed, and we do not present sermorelin as a currently-marketed finished drug or as a medicine to self-administer.
What the modifier means
Many domains in this space carry a modifier — "order," "clinic," "doctor," "rx." On this site that modifier is editorial framing: a position the publisher occupies relative to the research, not a claim about services rendered. We do not offer treatment, consultation, or prescriptions, and we have no doctors, pharmacists, or clinical team. We are a reading desk for the published science on GHRH(1-29), and the research-grade sermorelin we describe is supplied for laboratory research only.